A stability-indicating reversed-phase high-performance liquid chromatography method for Ambrisentan: an endothelin receptor antagonist.
A stability-indicating reversed-phase high-performance liquid chromatography (HPLC) method was developed for the determination of ambrisentan, a drug used in the treatment of pulmonary hypertension. The desired chromatographic separation was achieved on a Kromasil C18 column (250 × 4.6 mm, 5 µm) using the mobile phase acetonitrile-ammonium formate (pH 3.0; 0.02 M) in gradient mode. The flow rate was set at 1.0 mL/min, and chromatograms were extracted at 262 nm using a photodiode array detector. The method was successfully validated in accordance to International Conference on Harmonization (ICH) guidelines acceptance criteria for linearity, accuracy, precision, robustness and forced degradation studies, which further proved the stability-indicating power. Linearity of ambrisentan peak area responses was demonstrated within the concentration range of 25-200 µg/mL. The limits of detection and quantitation were 0.2 and 0.6 µg/mL, respectively. Forced degradation studies were performed on ambrisentan bulk drug samples as per ICH guidelines to demonstrate the stability-indicating power of the HPLC method. Significant degradation was observed during acidic hydrolysis, neutral hydrolysis and oxidative stress. The degradation products were well resolved from primary peak of ambrisentan, indicating that the method is specific and stability indicating. The newly developed method is applicable for assay determination of active pharmaceutical ingredient.